We will also consider likely mediators of acquired resistance to such therapies, particularly Forkhead box protein M1 (FOXM1) and programmed death-ligand 1 (PD-L1) (Figure 1), whose simultaneous inhibition may be needed to achieve sustained, and possibly curative, anti-tumor activity. This evidence concerns the gene FOXM1 and neoplasm.